ALMS stock forecast, quote, news & analysis
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases... Show more
Alumis Inc. (ALMS) Stock Analysis: Phase 3 Triumph Ignites Momentum
Key Takeaways
- Alumis Inc. (ALMS) shares have shown strong upward momentum in recent weeks, driven by positive Phase 3 data for envudeucitinib in plaque psoriasis.
- The oral TYK2 inhibitor met all primary and secondary endpoints, achieving leading skin clearance rates among next-generation oral therapies.
- A $300 million upsized public offering bolstered the balance sheet, extending cash runway into late 2027.
- Analysts have raised price targets, with an average of $37.25, reflecting optimism around the psoriasis NDA and lupus trial readout.
- Pipeline expansion includes A-005 for neuroinflammatory diseases, positioning Alumis for multiple immune-mediated disorder opportunities.
- Recent trading reflects heightened investor interest amid clinical milestones and favorable safety profile.
Current Market Snapshot
In recent trading sessions, Alumis Inc. (ALMS) stock has exhibited robust performance within the biotechnology sector, buoyed by key clinical advancements and capital strengthening. The shares have navigated volatility typical of clinical-stage biopharma names, with notable gains tied to breakthrough trial results and strategic financing. Trading near the upper end of its recent range, ALMS reflects growing confidence in its precision-targeted therapies for autoimmune conditions. Broader market sentiment toward innovative immunology assets has supported the upward trajectory, as investors weigh the potential of oral TYK2 inhibitors against competitive landscapes. Volume patterns underscore sustained engagement from institutional players monitoring pipeline catalysts.
Recent Developments Driving ALMS Price Action
Alumis Inc. (ALMS) has experienced significant price appreciation in recent weeks, primarily propelled by transformative clinical data and financial maneuvers. On January 6, 2026, the company announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 trials evaluating envudeucitinib, a next-generation oral allosteric TYK2 inhibitor, in over 1,700 patients with moderate-to-severe plaque psoriasis. The trials met all primary and secondary endpoints with high statistical significance (p < 0.0001), demonstrating superior skin clearance versus placebo and active comparator apremilast.
At Week 16, approximately 74% of envudeucitinib-treated patients achieved PASI 75 (75% improvement in Psoriasis Area and Severity Index), and 59% reached sPGA 0/1 (clear or almost clear skin per static Physician’s Global Assessment). Responses deepened over time, with ~65% hitting PASI 90 and over 40% achieving PASI 100 by Week 24—rates positioning envudeucitinib as a leader among oral psoriasis therapies. Rapid onset was evident, with PASI 90 separation from placebo by Week 4. Patient-reported outcomes showed clinically meaningful improvements in quality of life and itch. The safety profile remained consistent with prior phases, featuring no new signals; common adverse events included headache, nasopharyngitis, and upper respiratory infections.
This readout triggered an immediate stock surge, with shares more than doubling in value shortly after, as it de-risked the asset and highlighted its potential best-in-class profile in a market favoring convenient oral options over injectables. Following the data release, Alumis capitalized on the momentum with a proposed $175 million public offering of common stock announced January 6, quickly upsized and priced on January 7 at $17.00 per share for 17.65 million shares, raising ~$300 million gross proceeds. Underwriters fully exercised their option for additional shares, closing the offering on January 9. The influx extended cash reserves to ~$630 million (including prior holdings), funding operations into Q4 2027 and supporting further development.
Analyst reactions amplified the bullish sentiment. HC Wainwright hiked its price target to $40 from $20 on January 9, citing reduced regulatory risk and elevated revenue potential. Morgan Stanley raised to $33 from $22 (Overweight) on January 7, boosting probability of success to 80%. Chardan initiated Buy coverage January 21 with $37, emphasizing late-stage pipeline strength. Consensus now stands at ~$37.25 (high $50), with Strong Buy ratings predominant.
Additional catalysts included February 5 announcement of participation in investor conferences (e.g., Guggenheim Summit, Oppenheimer Healthcare), where management recapped Phase 3 wins, NDA plans, and lupus progress. At Guggenheim, executives highlighted rapid onset, deep clearance, and upcoming ONWARD3 durability data (Q2–Q3 2026). Insider buying and activist interest further supported sentiment. Macro factors, like optimism in immunology amid TYK2 class validation, contributed, though biotech sector rotations introduced some pullbacks. Overall, these events linked directly to ALMS price strength, shifting investor focus from cash burn to commercialization prospects.
2026 Outlook and Key Factors to Monitor
As Alumis advances through 2026, investors should track pivotal milestones in its TYK2-focused pipeline. The company plans an NDA submission for envudeucitinib in psoriasis during the second half, pending confirmatory durability data from the ONWARD3 long-term extension (expected Q2–early Q3). Full Phase 3 results presentations at medical congresses will provide deeper insights into maintenance, safety, and comparators. Topline from the potentially pivotal Phase 2b LUMUS trial in systemic lupus erythematosus (SLE) is slated for Q3, assessing maximal IFN pathway inhibition's potential in this ~$11 billion market by 2032.
Broader pipeline progression includes Phase 2 initiation for A-005, a CNS-penetrant TYK2 inhibitor, in multiple sclerosis (H1) and neuroinflammatory indications, tapping ~$40 billion psoriasis and neuro markets. Preclinical IRF5 and other targets via proprietary analytics platform could yield updates. Regulatory feedback, label negotiations, and pricing dynamics post-NDA will shape trajectories. Competitive positioning against established TYK2s (e.g., deucravacitinib) hinges on superior efficacy-safety balance. Cash position supports runway, but dilution risks persist. Macro immunology trends, trial executions, and partnerships remain critical monitors for sustained value creation in immune-mediated diseases.
ALMS's RSI Oscillator ascending out of oversold territory
The RSI Indicator for ALMS moved out of oversold territory on June 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 12 similar instances when the indicator left oversold territory. In of the 12 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 12, 2026. You may want to consider a long position or call options on ALMS as a result. In of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ALMS just turned positive on June 11, 2026. Looking at past instances where ALMS's MACD turned positive, the stock continued to rise in of 17 cases over the following month. The odds of a continued upward trend are .
ALMS moved above its 50-day moving average on June 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMS advanced for three days, in of 112 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for ALMS crossed bearishly below the 50-day moving average on May 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ALMS broke above its upper Bollinger Band on June 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALMS entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.179) is normal, around the industry mean (18.720). P/E Ratio (0.166) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). ALMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (277.778) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement